The Investigational Drug Program is a comprehensive unit offering a full range of services in three basic areas: i) preclinical drug assessment, ii) formal investigational drug development and iii) clinical trials conducted at the BCCA. IDP staff have expertise with a variety of drug classes, including conventional small molecule drugs and immunotherapy through to gene therapy approaches. Services offered include cell culture and characterisation, drug cytotoxicity testing, in vivo tumour model development and efficacy studies, analytical development, validation and stability studies, and finally, aseptic parenteral manufacturing for GLP toxicology or Phase I/II clinical trials.
BC Cancer Agency Company Business Activity
Research and Development in the Physical, Engineering and Life Sciences